Total Payments
$786,068
2024 Payments
$3,535
Companies
49
Transactions
966
Medicare Patients
11,603
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$650,567 (82.8%)
Travel$88,123 (11.2%)
Consulting$28,404 (3.6%)
Food & Beverage$18,915 (2.4%)
Education$59.67 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $641,087 | 227 | 81.6% |
| Travel and Lodging | $88,123 | 293 | 11.2% |
| Consulting Fee | $28,404 | 10 | 3.6% |
| Food and Beverage | $18,915 | 424 | 2.4% |
| Honoraria | $9,480 | 6 | 1.2% |
| Education | $59.67 | 6 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $315,991 | 349 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $245,971 | 219 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $144,906 | 164 | $0 (2024) |
| Akcea Therapeutics, Inc. | $20,600 | 25 | $0 (2021) |
| Merck Sharp & Dohme LLC | $13,106 | 25 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $11,577 | 11 | $0 (2019) |
| PORTOLA PHARMACEUTICALS, INC. | $9,556 | 16 | $0 (2018) |
| Boston Scientific Corporation | $7,111 | 16 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $6,558 | 19 | $0 (2022) |
| Medtronic, Inc. | $3,760 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,535 | 22 | E.R. Squibb & Sons, L.L.C. ($3,150) |
| 2023 | $2,860 | 27 | E.R. Squibb & Sons, L.L.C. ($2,467) |
| 2022 | $30,979 | 61 | PFIZER INC. ($20,981) |
| 2021 | $28,434 | 45 | PFIZER INC. ($10,114) |
| 2020 | $54,586 | 60 | PFIZER INC. ($38,287) |
| 2019 | $175,607 | 214 | PFIZER INC. ($87,446) |
| 2018 | $225,169 | 250 | Novartis Pharmaceuticals Corporation ($91,061) |
| 2017 | $264,898 | 287 | Novartis Pharmaceuticals Corporation ($97,654) |
All Payment Transactions
966 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $28.47 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $4.82 | General |
| Category: Cardiovascular | ||||||
| 09/18/2024 | ATRICURE, INC. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/05/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $1.38 | General |
| Category: Cardiovascular | ||||||
| 08/29/2024 | Medtronic, Inc. | LINQ II (Device) | Food and Beverage | In-kind items and services | $30.04 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 08/21/2024 | Medtronic, Inc. | LINQ II (Device) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 06/28/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $8.80 | General |
| Category: Cardiovascular | ||||||
| 06/28/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $3.55 | General |
| Category: Cardiovascular | ||||||
| 06/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/14/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $6.72 | General |
| Category: Cardiovascular | ||||||
| 05/02/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $34.47 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 04/30/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $26.02 | General |
| Category: Not Applicable | ||||||
| 04/23/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/18/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $25.17 | General |
| Category: Cardiology | ||||||
| 04/15/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/01/2024 | Abbott Laboratories | AMPLATZER AMULET (Device) | Food and Beverage | In-kind items and services | $56.58 | General |
| Category: Structural Heart | ||||||
| 03/21/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/28/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: Cardiovascular | ||||||
| 02/13/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $15.17 | General |
| Category: Cardiology | ||||||
| 02/08/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $22.11 | General |
| Category: Heart Failure and Hypertension | ||||||
| 01/23/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/15/2023 | CARDIVA MEDICAL, INC. | CARDIVA VASCADE MVP VVCS 6-12F (Device) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: DEVICES | ||||||
| 11/07/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/27/2023 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 3,048 | 5,186 | $667,236 | $266,836 |
| 2022 | 27 | 2,977 | 5,076 | $652,578 | $271,989 |
| 2021 | 26 | 2,856 | 5,161 | $635,882 | $274,209 |
| 2020 | 27 | 2,722 | 4,695 | $588,702 | $235,043 |
Total Patients
11,603
Total Services
20,118
Medicare Billing
$1.0M
Procedure Codes
109
All Medicare Procedures & Services
109 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 682 | 1,374 | $254,190 | $124,584 | 49.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 221 | 239 | $95,600 | $32,561 | 34.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 698 | 1,433 | $60,186 | $15,175 | 25.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 84 | 86 | $25,800 | $11,801 | 45.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 79 | 152 | $15,200 | $9,515 | 62.6% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 58 | 58 | $21,170 | $8,193 | 38.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 46 | 57 | $14,250 | $7,190 | 50.5% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 40 | 235 | $16,450 | $6,482 | 39.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $12,540 | $5,502 | 43.9% |
| 93888 | Ultrasound of within the brain blood flow | Office | 2023 | 56 | 56 | $10,640 | $5,482 | 51.5% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 120 | 123 | $24,600 | $5,463 | 22.2% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 24 | 24 | $16,800 | $5,083 | 30.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 34 | 34 | $12,240 | $4,943 | 40.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 492 | 595 | $23,800 | $3,712 | 15.6% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 35 | 60 | $7,500 | $3,604 | 48.1% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 30 | 169 | $9,340 | $3,285 | 35.2% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 59 | 64 | $12,800 | $3,272 | 25.6% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 47 | 110 | $8,250 | $2,547 | 30.9% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 47 | 110 | $7,700 | $1,853 | 24.1% |
| 93463 | Drug infusion during cardiac catheterization | Facility | 2023 | 18 | 18 | $3,600 | $1,389 | 38.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 25 | 25 | $3,950 | $1,327 | 33.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 14 | $2,100 | $1,319 | 62.8% |
| 93290 | Evaluation of implantable heart and blood vessel monitoring system | Office | 2023 | 20 | 28 | $1,680 | $982.52 | 58.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $1,560 | $812.68 | 52.1% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 41 | 43 | $4,300 | $437.74 | 10.2% |
About Dr. Vance Wilson, MD
Dr. Vance Wilson, MD is a Cardiovascular Disease healthcare provider based in Daytona Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487614947.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vance Wilson, MD has received a total of $786,068 in payments from pharmaceutical and medical device companies, with $3,535 received in 2024. These payments were reported across 966 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($641,087).
As a Medicare-enrolled provider, Wilson has provided services to 11,603 Medicare beneficiaries, totaling 20,118 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 109 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology
- Location Daytona Beach, FL
- Active Since 03/27/2006
- Last Updated 10/10/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1487614947
Products in Payments
- ELIQUIS (Drug) $392,563
- ENTRESTO (Drug) $245,935
- VYNDAQEL (Drug) $68,294
- TEGSEDI (Drug) $20,600
- VERQUVO (Drug) $13,106
- PRALUENT (Biological) $11,577
- BEVYXXA (Drug) $9,556
- WATCHMAN (Device) $7,096
- FARXIGA (Drug) $6,507
- KENGREAL (Drug) $2,860
- Resolute (Device) $2,823
- Repatha (Biological) $951.62
- RESOLUTE ONYX (Device) $875.55
- Vascepa (Drug) $209.56
- ONPATTRO (Drug) $153.43
- Impella (Device) $134.25
- JARDIANCE (Drug) $93.07
- Irrisept (Device) $92.02
- AMPLATZER AMULET (Device) $87.48
- BRILINTA (Drug) $69.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Daytona Beach
Dinesh Arab, M.d, M.D
Cardiovascular Disease — Payments: $156,247
Cardiovascular Disease $156,247
David Henderson, M.d, M.D
Cardiovascular Disease — Payments: $142,000
Cardiovascular Disease $142,000
Dr. Humayun Jamidar, M.d, M.D
Cardiovascular Disease — Payments: $17,982
Cardiovascular Disease $17,982
Mr. Barry Kusnick, M.d, M.D
Cardiovascular Disease — Payments: $16,842
Cardiovascular Disease $16,842
Abdelrahman Aljadi, Md, MD
Cardiovascular Disease — Payments: $4,971
Cardiovascular Disease $4,971
Dr. Ryan Smith, D.o, D.O
Cardiovascular Disease — Payments: $4,801
Cardiovascular Disease $4,801